Nasdaq-listed Canton Strategic Holdings said the sale of its biotech research unit, Gravitas Life Sciences, has been completed. According to Odaily, the buyer was Gravitas Collective Corp, and the transaction was unanimously approved by the company’s board and closed on July 17, 2026.
The company said it will focus on the Canton Network ecosystem and shift toward digital financial services, with an emphasis on asset tokenization, financial digitization, and compliance-focused financial infrastructure.
Canton Strategic Holdings Completes Gravitas Life Sciences Sale
2026-07-23 12:23:43
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Cellnex Studies Strategic Options After Share Price Slump
